← boardnext 2026-11-15
ACHV
Achieve Life Sciencesdistress 7/10 · high distress / dilution risk$6.18-2%today-5% from 52w high
Lead: Vaping Cessation · target Nicotinic AChR
Revenue
pre-revenue
Liquidity
$29M
Runway
0.7 yrs
Shares 1y
+101%
Price & events
+12.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.1%
1D
+3.7%
1W
+23.4%
1M
+48.9%
3M
+10.4%
6M
+126.4%
1Y
+20.2%
2Y
-20.6%
5Y
-21.8%
All
Overview
- Market Cap
- $634.43M
- Volume
- 132.33K
- 52 Week Range
- $2.32 – $6.53
- Total Shares
- 102.66M
- Float Shares
- 87.47M
- Short %
- 12.32%
- % Held by Insiders
- 0.93%
- % Held by Institutions
- 63.63%
- RVOL
- 0.06x
- Beta
- 2.22
Pipeline stages · 1 programs
Cytisinicline
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11-15 Estimated 50% readout ~2027-01-29 | Phase 3 | Cytisiniclinebreakthrough | Vaping Cessation | — | not yet recruiting |
| 2025-09-29 | Phase 3 | Cytisiniclinebreakthrough | Smoking Cessation, Vaping Cessation | 479 | completed |
Catalyst news & presentations · 3
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-04-15partnershipEntered securities purchase agreement with investors, raising approximately $180 million.SEC 8-K
- June 2025regulatory submissionFiled (NDA/BLA)cytisinicline · NDA submission for cytisinicline as a treatment for nicotine dependence for smoking cessation.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $14 (+123% upside) · 10 analysts
- 2026-06-22HC Wainwright & Co.Buy
- 2026-04-21Canaccord GenuityBuy
- 2026-04-16HC Wainwright & Co.Buy
- 2026-03-25HC Wainwright & Co.Buy
- 2025-11-25CitizensMarket Outperform
- 2025-08-21HC Wainwright & Co.Buy
Competitors — Nicotinic AChR
- none identified
Recent news
- 2026-07-18ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally? - Stocktwits
- 2026-07-17Achieve Life Sciences (NASDAQ:ACHV) Stock Price Up 6.5% - Here's Why - MarketBeat
- 2026-07-14Canaccord reiterates Achieve Life Sciences stock rating on CRL review - Investing.com
- 2026-07-14Canaccord reiterates Achieve Life Sciences stock rating on CRL review By Investing.com - Investing.com Canada
- 2026-07-10Achieve Life Sciences (NASDAQ:ACHV) Trading Down 7.7% - Should You Sell? - MarketBeat
- 2026-07-09Achieve Life Sciences Inc. (ACHV) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
- 2026-07-09Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting - Yahoo Finance
- 2026-07-08Vivo Opportunity group reports 5.0% stake in Achieve Life Sciences | ACHV SEC Filing - Form SCHEDULE 13G - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.